Spyre Therapeutics Commences Public Offering of Common Stock
MT newswire2026/10/05 20:1704:17 PM EDT, 10/05/2026 (MT Newswires) -- Spyre Therapeutics (SYRE) has begun an underwritten public offering of its common stock, subject to market and other conditions, it said Monday. The company said it is expects to grant the underwriters a 30-day option to buy an additional 15% of the common shares offered in the public offering. Spyre plans to use the net proceeds to advance its programs in gastroenterology, rheumatology, and dermatology. Any remaining proceeds will be used for ongoing research and development, working capital and general corporate purposes, the company added.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Crypto prices
More
